Antimycobacterial Drugs Flashcards

1
Q

Treatment: M. tuberculosis

A

Rifampin

Isoniazid

Pyrazinamide

Ethambutol

(RIPE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treatment: M. leprae

(lepromatous form)

A

Long-term Dapson + Rifampin

+ Clofazimine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Prophylaxis: M. avium-intracellulare

A

Azithromycin

Rifabutin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Clinical use: Ethambutol

A
  1. Mycobacterium tuberculosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Treatment: M. leprae

(tuberculoid form)

A

Long-term Dapson + Rifampin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical use: Rifamycins

Rifampin

Rifabutin

A
  1. Mycobacterium tuberculosis
  2. Leprosy: Delays resistance to Dapsone
  3. Prophylaxis:
    • N. meningitidis (meningitis)
    • Haemophilus influenza type B (meningitis)
  4. Rifabutin favored over Rifampin in HIV due to less P-450 stimulation (reduces protease inhibitor concentrations)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Mechanism: Rifamycins

Rifampin

Rifabutin

A

RNA synthesis inhibitor:

Inhibit DNA-dependent RNA polymerase → inhibiting bacterial RNA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Mechanism: Isoniazid (INH)

A
  • Decrease synthesis of mycolic acids
    • Bacterial catalase-peroxidase (encoded by KatG) needed to convert INH to active metabolite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Mechanism: Pyrazinamide

A

Uncertain

Prodrug that is converted to the active compound pyrazinoic acid

Works best at acidic pH (e.g., host phagolysosomes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Adverse effects: Rifamycins

Rifampin

Rifabutin

A
  1. Minor hepatotoxicity
  2. Drug interactions (P-450 inducer)
  3. Orange body fluids (nonhazardous)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Resistance: Isoniazid

A

Mutations leading to underexpression of KatG

(encodes bacterial catalase peroxidase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Clinical use: Streptomycin

A
  1. Mycobacterium tuberculosis (2nd line)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Prophylaxis: M. tuberculosis

A

Isoniazid (INH)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adverse effects: Streptomycin

A
  1. Nephrotoxicity
  2. Tinnitus
  3. Vertigo
  4. Ataxia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adverse effects: Pyrazinamide

A
  1. Hyperuricemia
  2. Hepatotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Adverse effects: Isoniazid

A
  1. Hepatoxocity
  2. P-450 inhibition (vs Rifampin)
  3. Drug-induced SLE
  4. Anion gap metabolic acidosis
  5. Vitamin B6 deficiency → peripheral neuropathy, sideroblastic anemia (administer with pyridoxine)
17
Q

Treatment: M. avium-intracellulare

A

More drug resistant than M. tuberculosis

Macrolide + Ethanbutol

Can add Rifabutin or Ciprofloxacin

18
Q

Clinical use: Pyrazinamide

A
  1. Mycobacterium tuberculosis
19
Q

Note that Isoniazid half-lives vary based on whether the patient is a fast or slow ___.

A

Acetylator

(N-acetyltransferase)

20
Q

Mechanism: Streptomycin

A

Aminoglycoside

Interferes with 30S component of ribosome

21
Q

Resistance: Rifamycins

Rifampin

Rifabutin

A

Mutations reduce drug binding to RNA polymerase (necessary for RNA synthesis)

Monotherapy rapidly leads to resistance

22
Q

Adverse effects: Ethambutol

A
  1. Optic neuropathy (red-green color blindness)
23
Q

Mechanism: Ethambutol

A

Arabinogalactan synthesis inhibitor:

Decrease carbohydrate polymerization of mycobacterium cell wall by blocking arabinosyl transferase

24
Q

Clinical use: Isoniazid

A
  1. Mycobacterium tuberculosis
  2. The only agent used as solo prophylaxis to TB
  3. Monotherapy for latent TB